Forbes
“Over the past two decades, the field of medical genomics underwent nothing less than a revolution in terms of both technological advancement and accumulated knowledge. even though the technologies to help diagnose patients with rare genetic diseases exist, the rate of underdiagnoses and misdiagnoses is still alarmingly high, and patients who receive diagnoses end up waiting too long for them, sometimes years. FDNA, a leading digital health company, our mission is to end the diagnostic odyssey for undiagnosed pediatric patients with rare diseases. I’ve seen that the main contributors to this state of affairs are the excruciatingly long wait times for genetics appointments, coupled with the significant workforce shortage of experts in the field.”
The article emphasizes the crucial role of access and actionability in genetic testing and precision medicine, highlighting FDNA’s technological advancements. FDNA uses facial recognition software to expedite the diagnosis of rare genetic disorders, making genetic testing more efficient and actionable. This AI-driven approach allows for prompt and accurate diagnoses, ensuring that patients receive timely and appropriate care. By enhancing the accessibility and practical application of genetic information, FDNA’s innovations are pivotal in propelling the field of precision medicine forward. The article highlights the transformative potential of integrating advanced technologies in genetic testing to improve patient outcomes.
